India-US Trade Deal Nears the Finish Line: Five Chemical and Industrial Exporters Set for a Margin Reboot
India and the United States concluded two days of trade talks on June 24, with Commerce Minister Piyush Goyal and US Trade Representative Jamieson Greer reviewing the core elements of a bilateral agreement. Multiple reports indicate the two sides are "very, very close" to a historic interim trade deal ahead of the July 24 tariff deadline. If finalized, effective US tariffs on many Indian exports would drop from a punitive 50% to roughly 18% — a seismic shift for companies whose margins have been squeezed for nearly a year.
For retail investors, the question is not whether a deal happens — the political will appears strong on both sides — but which companies stand to gain the most. We dug into quarterly filings, earnings call transcripts, and investor presentations of Indian exporters to find the ones with the clearest exposure.
Aarti Industries: The Most Direct Beneficiary
Aarti Industries (AARTIIND) is arguably the single largest Indian beneficiary of tariff normalization. The specialty chemicals maker exports four major products to the US — MMA, PDCB, MEA, and NCB — and three of the four were hit with full tariffs. Per their Q3 FY26 earnings call, management noted that the tariff reduction from "50% plus to now 18% plus" would result in "a margin that will accrue to all players in the value chain" and "directionally should lead to better realizations."
The numbers are already showing a recovery: Q3 FY26 revenue rose 22% year-on-year, EBITDA jumped 37%, and profit after tax surged 189%, partly because US volumes for MMA and PDCB resumed during the quarter. Their investor presentation explicitly flagged "upside possible in margins and PDA chain volumes linked to US-India trade deal." A formal deal would unlock the remaining upside.
PCBL Chemical: Stability Matters More Than the Rate
PCBL Chemical (PCBL), India's largest carbon black manufacturer, has a more nuanced story. US exports account for about 5% of its total volume, and the effective tariff was actually lower than the headline rate — roughly 4% — because PCBL sources carbon black feedstock (CBFS) from the US, which creates an offset. Even at the new 18% rate, the effective rate would be about 8-9%.
But in their Q3 FY26 earnings call, management said they expect "significant improvement" in both margins and volumes, because "customers were more worried about the instability" than the rate itself. By Q4 FY26, management confirmed that US volumes were already recovering and "reducing the pressure on pricing in India." Consolidated Q3 revenue stood at Rs 1,846 crore with EBITDA of Rs 231 crore.
Ester Industries: Double Tailwind
Ester Industries (ESTER), a BOPET film and specialty polymer maker, has been caught in a double bind: US tariffs of 50% on one side, and Chinese dumping of BOPET film at predatory prices on the other. Per their Q3 FY26 earnings call, management said the India-US trade deal "is likely to reduce the tariff from 50% to 18%" and that "this shift is expected to boost margins and thereby performance in upcoming quarters."
Q3 FY26 revenue was Rs 343.5 crore with an EBITDA margin of just 6.1% — compressed specifically by the US tariff. The company now has a double tailwind: tariff relief from the trade deal, and the DGTR's newly imposed anti-dumping duties on Chinese BOPET film imports, which per their Q4 FY26 investor presentation drove domestic margin expansion.
Jubilant Ingrevia: Choline Shows the Playbook
Jubilant Ingrevia (JUBLINGREA) offers a real-time preview of what tariff relief looks like. Per their Q3 FY26 earnings call, management noted that only 2% of their portfolio was directly impacted by US tariffs. But in one product — choline chloride — where they already received a favorable tariff structure versus Chinese competitors, "our share has already started to increase and we have started to book volumes in the European market."
CEO Deepak Jain noted that the indirect impact is equally important: "Because of the uncertainty created by the delay in the US FTA, some customers had become tentative even on products which were not coming under any duty regime." A formal deal removes this uncertainty overhang across their entire US and EU order book.
Rico Auto: Orders Waiting on Certainty
Rico Auto Industries (RICOAUTO) exports precision auto components to US commercial vehicle manufacturers. While their direct tariff exposure is manageable — customers have been absorbing the 25-50% tariffs — the real story is about order flow. Per their Q2 FY26 earnings call, management confirmed "the customer is bearing that cost" on US exports. The company is targeting Rs 3,000 crore in revenue by FY27 at 13% margins, with exports as "better margin items."
A trade deal doesn't just lower costs for Rico — it unlocks pent-up orders. When customers face tariff uncertainty, they defer, split, or redirect orders. Stability brings commitment.
What Retail Investors Should Do
This is not a "buy the rumour" moment. These companies have already shown in their filings — with specific numbers and management commentary — how tariffs have hurt them and how a deal would help. The investment thesis rests on three pillars:
1. Direct margin recovery: Companies like Aarti Industries and Ester Industries have quantified the margin impact. A tariff drop from 50% to 18% flows almost directly to EBITDA.
2. Volume recovery: PCBL and Jubilant Ingrevia show that customers were holding back orders due to instability. A deal unlocks deferred demand.
3. Competitive repositioning vs China: India's tariff rate settling at 18% versus China's 100%+ creates a structural cost advantage for Indian chemical exporters.
Watch for the formal announcement before July 24. If it comes with the expected 18% rate, these five companies have the most filing-backed evidence of upside. If it doesn't, revisit — the tariff pain is already priced into their recent quarters.
Data sourced from company filings on NSE via Xaro.